Orion Market Research Pvt. Ltd. info@omrglobal.com +91 780-304-0404
Help Center
Careers
Contact

Therapeutic Vaccine Market

Therapeutic Vaccine Market Size, Share & Trends Analysis Report, By Vaccine Type (Cancer Therapeutic Vaccines, Infectious Disease Therapeutic Vaccines, Autoimmune Disease Vaccines, Neurological Disorder Vaccines), By Technology Platform (mRNA Vaccines, DNA Vaccines, Peptide/Protein-Based Vaccines, Dendritic Cell Vaccines, Viral Vector-Based Vaccines, Whole Cell Vaccines), By End User (Hospitals, Specialty Clinics, Research Institutes, Ambulatory Surgical Centers), Forecast Period (2026-2035)

Published: Jun 2026 | Report Code: OMR2029808 | Category : Pharmaceuticals | Delivery Format: /

Industry Overview

The global therapeutic vaccine market is experiencing significant growth, driven by rising disease burden and rapid advancements in immunotherapy technologies. The market was valued at $17.1 billion in 2025 and is projected to reach $47.6 billion by 2035, expanding at a CAGR of 10.8% during 2026–2035.

A major growth driver is the increasing prevalence of cancer and chronic diseases. According to the World Health Organization (WHO), cancer accounted for nearly 10 million deaths globally in 2022, highlighting the urgent need for advanced therapeutic solutions. Therapeutic vaccines, particularly in oncology, are gaining traction due to their ability to stimulate targeted immune responses and improve survival rates.

Additionally, data from the U.S. Food and Drug Administration (FDA) shows a steady increase in approvals for biologics and immunotherapies, reflecting the growing acceptance of innovative treatment modalities. The integration of mRNA technology, personalized medicine, and combination therapies is further accelerating market expansion.

Major end-use industries include hospitals, oncology specialty clinics, research institutes, and ambulatory surgical centers, where demand for advanced immunotherapy solutions continues to rise.

Market Dynamics

Driver: Rising Global Cancer Burden Driving Demand for Therapeutic Vaccines

The increasing incidence of cancer is a key factor fueling the growth of the therapeutic vaccine market. According to the International Agency for Research on Cancer (IARC), global cancer cases are projected to reach over 35 million by 2050, significantly increasing demand for innovative treatment solutions. Therapeutic vaccines offer targeted treatment by activating the immune system, making them highly effective in oncology.

Furthermore, the Pharmaceutical Research and Manufacturers of America (PhRMA) reports that more than 1,800 cancer medicines are currently in development, many of which include immunotherapies and therapeutic vaccines. In 2025–2026, companies are heavily investing in mRNA-based cancer vaccines and personalized immunotherapy platforms to improve treatment outcomes. Strategic collaborations, such as partnerships between biotech firms and pharmaceutical companies, are accelerating clinical trials and commercialization efforts.

Challenge: High Development Costs and Regulatory Complexity

Despite strong growth prospects, the therapeutic vaccine market faces significant challenges related to high R&D costs and complex regulatory pathways. Developing therapeutic vaccines involves extensive clinical trials, which can take several years and require substantial investment.

According to the U.S. FDA, the approval process for biologics and advanced therapies involves rigorous safety and efficacy evaluations, increasing time-to-market. Additionally, manufacturing complexities associated with personalized vaccines and mRNA platforms pose scalability challenges.

Supply chain constraints, particularly for specialized raw materials and cold-chain logistics, further impact production and distribution. However, companies are addressing these challenges through investments in advanced manufacturing technologies, strategic partnerships, and capacity expansion initiatives.

Market Segmentation

  • Based on the vaccine type, the market is segmented into cancer therapeutic vaccines, infectious disease therapeutic vaccines, autoimmune disease vaccines, and neurological disorder vaccines.
  • Based on the technology platform, the market is segmented into mrna vaccines, dna vaccines, peptide/protein-based vaccines, dendritic cell vaccines, viral vector-based vaccines, and whole cell vaccines.
  • Based on the end user, the market is segmented into hospitals, specialty clinics (oncology & immunology centers), research institutes, and ambulatory surgical centers.

Cancer Therapeutic Vaccines Segment Leads the Market

The cancer therapeutic vaccines segment dominates the market due to the increasing global cancer burden and rising adoption of immunotherapy. These vaccines are widely used in treating prostate cancer, melanoma, and lung cancer.

Healthcare institutions and oncology centers are increasingly adopting therapeutic vaccines as part of combination therapies with checkpoint inhibitors. Between 2022–2026, companies have focused on expanding their oncology pipelines, with increased investments in clinical trials and product development.

mRNA Vaccines Segment to Record Strong Growth

The mRNA vaccines segment is expected to witness the fastest growth due to its high efficacy, rapid development capabilities, and scalability. The success of mRNA technology in infectious diseases has accelerated its adoption in oncology.

Emerging applications include personalized cancer vaccines targeting specific tumor mutations. Increased funding, technological advancements, and strategic collaborations are driving innovation in this segment.

Regional Outlook

The global therapeutic vaccine market is geographically segmented into North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa and Latin America).

Country Analysis

United States Leads the Market

The United States dominates the therapeutic vaccine market due to strong healthcare infrastructure and high investment in R&D. According to the U.S. FDA, the country leads globally in biologics approvals and clinical trials. Additionally, the National Cancer Institute reports that cancer remains a leading cause of death in the U.S., driving demand for advanced therapies.

Government initiatives supporting innovation and funding for cancer research further strengthen market growth.

China to Record Strong Growth

China is expected to witness rapid growth due to expanding healthcare infrastructure and increasing investments in biotechnology. According to the World Health Organization (WHO), China accounts for a significant share of global cancer cases.

The country is also investing heavily in domestic vaccine manufacturing and R&D capabilities. Growing clinical trial activity and government support for biotech innovation are driving market expansion.

Competitive Landscape

The therapeutic vaccine market is highly competitive, characterized by strong innovation and strategic collaborations. Leading players such as Moderna, BioNTech, Gilead Sciences (Kite Pharma), Dendreon Pharmaceuticals, and GlaxoSmithKline are focusing on expanding their product pipelines and enhancing technological capabilities. Companies are investing in mRNA technology, personalized vaccines, and combination therapies to strengthen their market position. Partnerships, acquisitions, and R&D investments are key strategies adopted to gain a competitive edge.

Recent Developments (2022-2026)

  • In January 2026, Moderna and Merck & Co. reported that their personalized mRNA cancer vaccine intismeran (mRNA-4157/V940), in combination with KEYTRUDA, demonstrated a sustained 49% reduction in the risk of recurrence or death at five years in melanoma patients. The results highlight the long-term durability and clinical potential of mRNA-based therapeutic vaccines, supporting future commercialization and market growth.
  • In April 2026, Scancell received Fast Track designation from the U.S. Food and Drug Administration for its DNA-based cancer vaccine iSCIB1+ for advanced melanoma. Phase 2 data showed improved progression-free survival, highlighting the growing potential of therapeutic cancer vaccines.

The Report Covers

  • Market value data analysis of 2025 and forecast to 2035.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global therapeutic vaccine market. Based on the availability of data, information related to new products and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying ‘who-stands-where’ in the market.
  1. Report Summary
  • Current Industry Analysis and Growth Potential Outlook
  • Global Therapeutic Vaccine Market Sales Analysis – Vaccine Type | Technology Platform | End User ($ Billion)
  • Therapeutic Vaccine Market Sales Performance of Top Countries

1.1 Research Methodology

  • Primary Research Approach
  • Secondary Research Approach

1.2 Market Snapshot

  1. Market Overview and Insights

2.1 Scope of the Study

2.2 Analyst Insight & Current Market Trends

2.2.1 Key Therapeutic Vaccine Market Trends

2.2.2 Market Recommendations

2.3 Porter's Five Forces Analysis for the Therapeutic Vaccine Market

2.3.1 Competitive Rivalry

2.3.2 Threat of New Entrants

2.3.3 Bargaining Power of Suppliers

2.3.4 Bargaining Power of Buyers

2.3.5 Threat of Substitutes

  1. Market Determinants

3.1 Market Drivers

3.1.1 Drivers For Global Therapeutic Vaccine Market: Impact Analysis

3.2 Market Pain Points and Challenges

3.2.1 Restraints For Global Therapeutic Vaccine Market: Impact Analysis

3.3 Market Opportunities

3.3.1 Opportunities For Global Therapeutic Vaccine Market: Impact Analysis

  1. Competitive Landscape

4.1 Competitive Dashboard – Therapeutic Vaccine Market Revenue and Share by Manufacturers

  • Therapeutic Vaccine Product Comparison Analysis
  • Top Market Player Ranking Matrix

4.2 Key Company Analysis

4.2.1 Moderna

4.2.1.1 Overview

4.2.1.2 Product Portfolio

4.2.1.3 Financial Analysis

4.2.1.4 SWOT Analysis

4.2.1.5 Business Strategy

4.2.2 BioNTech

4.2.2.1 Overview

4.2.2.2 Product Portfolio

4.2.2.3 Financial Analysis

4.2.2.4 SWOT Analysis

4.2.2.5 Business Strategy

4.2.3 Gilead Sciences (Kite Pharma)

4.2.3.1 Overview

4.2.3.2 Product Portfolio

4.2.3.3 Financial Analysis

4.2.3.4 SWOT Analysis

4.2.3.5 Business Strategy

4.2.4 Dendreon Pharmaceuticals

4.2.4.1 Overview

4.2.4.2 Product Portfolio

4.2.4.3 Financial Analysis

4.2.4.4 SWOT Analysis

4.2.4.5 Business Strategy

4.2.5 GlaxoSmithKline

4.2.5.1 Overview

4.2.5.2 Product Portfolio

4.2.5.3 Financial Analysis

4.2.5.4 SWOT Analysis

4.2.5.5 Business Strategy

4.3 Top Winning Strategies by Market Players

4.3.1 Merger and Acquisition

4.3.2 Product Launch

4.3.3 Partnership And Collaboration

  1. Global Therapeutic Vaccine Market Sales Analysis by Vaccine Type ($ Billion)

5.1 Cancer Therapeutic Vaccines

5.2 Infectious Disease Therapeutic Vaccines

5.3 Autoimmune Disease Vaccines

5.4 Neurological Disorder Vaccines

  1. Global Therapeutic Vaccine Market Sales Analysis by Technology Platform ($ Billion)

6.1 mRNA Vaccines

6.2 DNA Vaccines

6.3 Peptide/Protein-Based Vaccines

6.4 Dendritic Cell Vaccines

6.5 Viral Vector-Based Vaccines

6.6 Whole Cell Vaccines

  1. Global Therapeutic Vaccine Market Sales Analysis by End User ($ Billion)

7.1 Hospitals

7.2 Specialty Clinics (Oncology & Immunology Centers)

7.3 Research Institutes

7.4 Ambulatory Surgical Centers

  1. Regional Analysis

8.1 North American Therapeutic Vaccine Market Sales Analysis – Vaccine Type | Technology Platform | End User | Country ($ Billion)

8.1.1 United States

8.1.2 Canada

8.2 European Therapeutic Vaccine Market Sales Analysis – Vaccine Type | Technology Platform | End User | Country ($ Billion)

8.2.1 UK

8.2.2 Germany

8.2.3 Italy

8.2.4 Spain

8.2.5 France

8.2.6 Russia

8.2.7 Rest of Europe

8.3 Asia-Pacific Therapeutic Vaccine Market Sales Analysis – Vaccine Type | Technology Platform | End User | Country ($ Billion)

8.3.1 China

8.3.2 Japan

8.3.3 South Korea

8.3.4 India

8.3.5 Australia & New Zealand

8.3.6 ASEAN Countries

8.3.7 Rest of Asia-Pacific

8.4 Rest of the World Therapeutic Vaccine Market Sales Analysis – Vaccine Type | Technology Platform | End User | Country ($ Billion)

8.4.1 Latin America

8.4.2 Middle East and Africa

  1. Company Profiles

9.1  Anixa Biosciences

9.1.1 Quick Facts

9.1.2 Company Overview

9.1.3 Product Portfolio

9.1.4 Business Strategies

9.2  Argos Therapeutics

9.2.1 Quick Facts

9.2.2 Company Overview

9.2.3 Product Portfolio

9.2.4 Business Strategies

9.3  AstraZeneca

9.3.1 Quick Facts

9.3.2 Company Overview

9.3.3 Product Portfolio

9.3.4 Business Strategies

9.4  Bavarian Nordic

9.4.1 Quick Facts

9.4.2 Company Overview

9.4.3 Product Portfolio

9.4.4 Business Strategies

9.5  CureVac

9.5.1 Quick Facts

9.5.2 Company Overview

9.5.3 Product Portfolio

9.5.4 Business Strategies

9.6  Dynavax Technologies

9.6.1 Quick Facts

9.6.2 Company Overview

9.6.3 Product Portfolio

9.6.4 Business Strategies

9.7  GeoVax Labs

9.7.1 Quick Facts

9.7.2 Company Overview

9.7.3 Product Portfolio

9.7.4 Business Strategies

9.8  Heat Biologics (NightHawk Biosciences)

9.8.1 Quick Facts

9.8.2 Company Overview

9.8.3 Product Portfolio

9.8.4 Business Strategies

9.9  Immatics

9.9.1 Quick Facts

9.9.2 Company Overview

9.9.3 Product Portfolio

9.9.4 Business Strategies

9.10 Imugene

9.10.1 Quick Facts

9.10.2 Company Overview

9.10.3 Product Portfolio

9.10.4 Business Strategies

9.11 Inovio Pharmaceuticals

9.11.1 Quick Facts

9.11.2 Company Overview

9.11.3 Product Portfolio

9.11.4 Business Strategies

9.12 Johnson & Johnson (Janssen)

9.12.1 Quick Facts

9.12.2 Company Overview

9.12.3 Product Portfolio

9.12.4 Business Strategies

9.13 Northwest Biotherapeutics

9.13.1 Quick Facts

9.13.2 Company Overview

9.13.3 Product Portfolio

9.13.4 Business Strategies

9.14 Novavax

9.14.1 Quick Facts

9.14.2 Company Overview

9.14.3 Product Portfolio

9.14.4 Business Strategies

9.15 OSE Immunotherapeutics

9.15.1 Quick Facts

9.15.2 Company Overview

9.15.3 Product Portfolio

9.15.4 Business Strategies

9.16 Pfizer

9.16.1 Quick Facts

9.16.2 Company Overview

9.16.3 Product Portfolio

9.16.4 Business Strategies

9.17 Sanofi

9.17.1 Quick Facts

9.17.2 Company Overview

9.17.3 Product Portfolio

9.17.4 Business Strategies

9.18 Transgene

9.18.1 Quick Facts

9.18.2 Company Overview

9.18.3 Product Portfolio

9.18.4 Business Strategies

9.19 Valneva

9.19.1 Quick Facts

9.19.2 Company Overview

9.19.3 Product Portfolio

9.19.4 Business Strategies

9.20 VBI Vaccines

9.20.1 Quick Facts

9.20.2 Company Overview

9.20.3 Product Portfolio

9.20.4 Business Strategies

1. Global Therapeutic Vaccine Market Research and Analysis by Vaccine Type, 2025–2035 ($ Billion) 

2. Global Cancer Therapeutic Vaccine Market Research and Analysis by Region, 2025–2035 ($ Billion) 

3. Global Infectious Disease Therapeutic Vaccine Market Research and Analysis by Region, 2025–2035 ($ Billion) 

4. Global Autoimmune Disease Vaccine Market Research and Analysis by Region, 2025–2035 ($ Billion) 

5. Global Neurological Disorder Vaccine Market Research and Analysis by Region, 2025–2035 ($ Billion) 

6. Global Therapeutic Vaccine Market Research and Analysis by Technology Platform, 2025–2035 ($ Billion) 

7. Global mRNA Vaccine Market Research and Analysis by Region, 2025–2035 ($ Billion) 

8. Global DNA Vaccine Market Research and Analysis by Region, 2025–2035 ($ Billion) 

9. Global Therapeutic Vaccine Market Research and Analysis by End User, 2025–2035 ($ Billion) 

10. Global Therapeutic Vaccine for Hospitals Market Research and Analysis by Region, 2025–2035 ($ Billion) 

11. Global Therapeutic Vaccine for Specialty Clinics (Oncology & Immunology Centers) Market Research and Analysis by Region, 2025–2035 ($ Billion) 

12. Global Therapeutic Vaccine for Research Institutes Market Research and Analysis by Region, 2025–2035 ($ Billion) 

13. Global Therapeutic Vaccine for Ambulatory Surgical Centers Market Research and Analysis by Region, 2025–2035 ($ Billion) 

14. Global Therapeutic Vaccine Market Research and Analysis by Region, 2025–2035 ($ Billion) 

15. North America Therapeutic Vaccine Market Research and Analysis by Country, 2025–2035 ($ Billion) 

16. North America Therapeutic Vaccine Market Research and Analysis by Vaccine Type, 2025–2035 ($ Billion) 

17. North America Therapeutic Vaccine Market Research and Analysis by Technology Platform, 2025–2035 ($ Billion) 

18. North America Therapeutic Vaccine Market Research and Analysis by End User, 2025–2035 ($ Billion) 

19. Europe Therapeutic Vaccine Market Research and Analysis by Country, 2025–2035 ($ Billion) 

20. Europe Therapeutic Vaccine Market Research and Analysis by Vaccine Type, 2025–2035 ($ Billion) 

21. Europe Therapeutic Vaccine Market Research and Analysis by Technology Platform, 2025–2035 ($ Billion) 

22. Europe Therapeutic Vaccine Market Research and Analysis by End User, 2025–2035 ($ Billion) 

23. Asia-Pacific Therapeutic Vaccine Market Research and Analysis by Country, 2025–2035 ($ Billion) 

24. Asia-Pacific Therapeutic Vaccine Market Research and Analysis by Vaccine Type, 2025–2035 ($ Billion) 

25. Asia-Pacific Therapeutic Vaccine Market Research and Analysis by Technology Platform, 2025–2035 ($ Billion) 

26. Asia-Pacific Therapeutic Vaccine Market Research and Analysis by End User, 2025–2035 ($ Billion) 

27. Rest of the World Therapeutic Vaccine Market Research and Analysis by Region, 2025–2035 ($ Billion) 

28. Rest of the World Therapeutic Vaccine Market Research and Analysis by Vaccine Type, 2025–2035 ($ Billion) 

29. Rest of the World Therapeutic Vaccine Market Research and Analysis by Technology Platform, 2025–2035 ($ Billion) 

30. Rest of the World Therapeutic Vaccine Market Research and Analysis by End User, 2025–2035 ($ Billion) 

31. Global Therapeutic Vaccine Market – Top 5 Companies Market Share Analysis, 2025 (%) 

32. Global Therapeutic Vaccine Market – Top 5 Companies Revenue Comparison, 2025–2035 ($ Billion) 

1. Global Therapeutic Vaccine Market Share by Vaccine Type, 2025 Vs 2035 (%) 

2. Global Cancer Therapeutic Vaccine Market Research and Analysis by Region, 2025 Vs 2035 (%) 

3. Global Infectious Disease Therapeutic Vaccine Market Research and Analysis by Region, 2025 Vs 2035 (%) 

4. Global Autoimmune Disease Vaccine Market Research and Analysis by Region, 2025 Vs 2035 (%) 

5. Global Neurological Disorder Vaccine Market Research and Analysis by Region, 2025 Vs 2035 (%) 

6. Global Therapeutic Vaccine Market Share by Technology Platform, 2025 Vs 2035 (%) 

7. Global mRNA Vaccine Market Research and Analysis by Region, 2025 Vs 2035 (%) 

8. Global DNA Vaccine Market Research and Analysis by Region, 2025 Vs 2035 (%) 

9. Global Therapeutic Vaccine Market Share by End User, 2025 Vs 2035 (%) 

10. Global Therapeutic Vaccine for Hospitals Market Research and Analysis by Region, 2025 Vs 2035 (%) 

11. Global Therapeutic Vaccine for Specialty Clinics (Oncology & Immunology Centers) Market Research and Analysis by Region, 2025 Vs 2035 (%) 

12. Global Therapeutic Vaccine for Research Institutes Market Research and Analysis by Region, 2025 Vs 2035 (%) 

13. Global Therapeutic Vaccine for Ambulatory Surgical Centers Market Research and Analysis by Region, 2025 Vs 2035 (%) 

14. Global Therapeutic Vaccine Market Share by Region, 2025 Vs 2035 (%) 

15. U.S. Therapeutic Vaccine Market Size, 2025–2035 ($ Billion) 

16. Canada Therapeutic Vaccine Market Size, 2025–2035 ($ Billion) 

17. UK Therapeutic Vaccine Market Size, 2025–2035 ($ Billion) 

18. France Therapeutic Vaccine Market Size, 2025–2035 ($ Billion) 

19. Germany Therapeutic Vaccine Market Size, 2025–2035 ($ Billion) 

20. Italy Therapeutic Vaccine Market Size, 2025–2035 ($ Billion) 

21. Spain Therapeutic Vaccine Market Size, 2025–2035 ($ Billion) 

22. Russia Therapeutic Vaccine Market Size, 2025–2035 ($ Billion) 

23. India Therapeutic Vaccine Market Size, 2025–2035 ($ Billion) 

24. China Therapeutic Vaccine Market Size, 2025–2035 ($ Billion) 

25. Japan Therapeutic Vaccine Market Size, 2025–2035 ($ Billion) 

26. South Korea Therapeutic Vaccine Market Size, 2025–2035 ($ Billion) 

27. Australia & New Zealand Therapeutic Vaccine Market Size, 2025–2035 ($ Billion) 

28. ASEAN Therapeutic Vaccine Market Size, 2025–2035 ($ Billion) 

29. Rest of Asia-Pacific Therapeutic Vaccine Market Size, 2025–2035 ($ Billion) 

30. Latin America Therapeutic Vaccine Market Size, 2025–2035 ($ Billion) 

31. Middle East & Africa Therapeutic Vaccine Market Size, 2025–2035 ($ Billion)

Choose License Type
    On Discount
Enterprise Custom
  • Printable version
  • No restriction to number of users within the company
CONTACT SALES

100%
Secured Payment

Why buy from us?
  • Covers more than 15 major industries, which are further segmented into 90+ sectors
  • 65% of our clients are loyal customers
  • 120+ countries are covered in analysis
  • currently servicing 1000+ customers globally
  • 100+ paid data sources mined to research
  • Our expert team will assist you with all research need and customization
  • Our expert research analyst will resolve your every query before and after purchasing the report
Related Reports

FAQS

The therapeutic vaccine market was valued at $17.1 billion in 2025 and is projected to reach $47.6 billion by 2035.
The market is expected to grow at a CAGR of 10.8% during the forecast period 2026–2035.
Cancer therapeutic vaccines dominate due to rising global cancer prevalence and strong adoption in oncology.
North America, particularly the United States, leads due to strong R&D investment and healthcare infrastructure.
The mRNA vaccines segment is the fastest growing due to technological advancements and personalized medicine adoption.